About
Resilience is a next-generation biomanufacturing CDMO built to overcome the complexity of modern therapeutics. The company offers an end-to-end suite of development and manufacturing services spanning biologics, cell therapy (autologous and allogeneic), and advanced drug product manufacturing. Its named solution platforms—Sprout Solutions™, Auto-T™, DAR-T™, Idea to Clinic™, and Build Your Resilience™—provide structured, milestone-driven pathways for drug substance, fill/finish, CAR-T manufacturing, and secondary supply readiness. Resilience operates commercially licensed facilities in Blue Ash (HQ), Cincinnati, Philadelphia, and Toronto, each specialized for distinct modalities including monoclonal antibodies, recombinant proteins, device assembly, packaging, and cell therapy release testing. The company's approach is rooted in platform-based strategies designed to reduce development timelines—offering clients up to 30% time savings from IND-enabling studies to clinic. Ideal for emerging biotech startups and established biopharma companies alike, Resilience positions itself as a collaborative partner with a culture of transparency and scientific rigor. Whether clients need clinical readiness in 12 months for T cell therapies or autologous CAR-T manufacturing in 3 days, Resilience provides the infrastructure, expertise, and supply chain support to make it happen. Resources include blogs, webinars, scientific articles, and expert insights on the future of advanced therapeutics.
Key Features
- Named Manufacturing Platforms: Structured solution platforms like Sprout Solutions™, Auto-T™, and DAR-T™ provide milestone-driven pathways for drug substance, fill/finish, and CAR-T manufacturing.
- End-to-End CDMO Capabilities: Covers the full development lifecycle from IND-enabling studies and tech transfer to commercial-scale manufacturing and supply chain support.
- Cell & Gene Therapy Specialization: Dedicated modular facilities and expertise for autologous and allogeneic cell therapies, including CAR-T manufacturing in as few as 3 days.
- Multi-Site North American Facilities: Commercially licensed sites in Blue Ash, Cincinnati, Philadelphia, and Toronto, each specialized for distinct biomanufacturing modalities.
- Secondary Supply & Risk Mitigation: Build Your Resilience™ offers three tiers of secondary supplier readiness with full access to quality, supply chain, and commercial support.
Use Cases
- Biotech startups seeking a CDMO partner to advance novel biologics from discovery through IND-enabling studies and first-in-human trials.
- Cell therapy developers needing flexible autologous or allogeneic manufacturing solutions with fast turnaround times for clinical programs.
- Established biopharma companies looking to add a secondary manufacturing supplier to de-risk commercial supply chains.
- Gene therapy organizations requiring specialized GMP manufacturing infrastructure and release testing capabilities.
- Drug product teams needing fill/finish, device assembly, and packaging services at a commercially licensed facility.
Pros
- Accelerated Timelines: Platform-based approaches deliver up to 30% time savings from concept to clinic, with some cell therapy programs reaching clinical readiness in 12 months.
- Broad Modality Coverage: Handles biologics, cell therapy, gene therapy, and drug product manufacturing under one roof across multiple specialized facilities.
- Collaborative Partnership Model: Emphasizes transparency and scientific partnership, providing clients with insight and control throughout the manufacturing process.
Cons
- Enterprise-Focused Pricing: Services are tailored for biopharma companies with established programs; smaller early-stage teams may find costs prohibitive without significant funding.
- North America Geography Only: Current manufacturing facilities are limited to North American sites, which may not suit clients requiring EU GMP or Asia-Pacific manufacturing.
Frequently Asked Questions
What types of therapies does Resilience manufacture?
Resilience specializes in biologics (monoclonal antibodies, recombinant proteins), autologous and allogeneic cell therapies (including CAR-T), and drug product manufacturing including fill/finish and device assembly.
How quickly can Resilience get a cell therapy to clinical readiness?
Through its Auto-T™ platform, Resilience can help T cell-based therapies achieve clinical readiness in as little as 12 months. Its DAR-T™ platform enables autologous CAR-T manufacturing in just 3 days.
Where are Resilience's manufacturing facilities located?
Resilience operates facilities in Blue Ash, OH (HQ), Cincinnati, OH; Philadelphia, PA; and Toronto, Canada—several of which are commercially licensed.
What is the Idea to Clinic™ program?
Idea to Clinic™ is a structured solution that guides biologics from early-stage development through IND submission and first-in-human trials, offering teams a 30% time savings compared to traditional approaches.
Does Resilience offer secondary supply services?
Yes. The Build Your Resilience™ program offers three levels of secondary supplier readiness, including full access to quality systems, supply chain infrastructure, and commercial manufacturing support.
